{"success":true,"data":{"pressRelease":{"id":"155138","rtpr_id":"nGNX6MjWrG-20260929","ticker":"CLRB","exchange":"NASDAQ","all_tickers":["CLRB"],"title":"Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia","author":"Globe Newswire","published_at":"2026-09-29T11:30:00.543Z","article_body":"Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and\nDuration of Response Exceeding 16 Months in Subset Analysis of Patients\nTreated with Iopofosine I 131 Immediately Post-BTKi Therapy\n\nData Further Support Company’s Plans to Advance Iopofosine I 131 in Phase 3\nConfirmatory Trial and Submit for U.S. Accelerated Market Approval in 1H27\n\nFLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences,\nInc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused\non the discovery and development of drugs for the treatment of cancer, today\nannounced that a subset analysis of data from the company’s Phase 2 CLOVER\nWaM clinical trial that support the potential of iopofosine I 131 as a\npotential treatment option for Waldenström Macroglobulinemia (WM) patients\nwho are refractory or resistant to BTK inhibitor therapy will be highlighted\nin a presentation at the upcoming International Workshop for Waldenström\nMacroglobulinemia (IWWM) taking place October 14 - 16, 2026 in Palm Springs,\nCalifornia.\n\n“We are pleased to present these data from the CLOVER-WaM study at IWWM and\nshare additional evidence supporting the potential of iopofosine I 131 to\naddress a significant unmet need for patients with WM. This analysis evaluated\npatients who received iopofosine I 131 immediately following BTK inhibitor\ntherapy after at least two prior lines of treatment, representing a\nparticularly challenging, heavily pretreated population,” said Jarrod\nLongcor, chief operating officer at Cellectar Biosciences. “We remain\non-target to dose patients in the confirmatory Phase 3 clinical trial in early\n2027 and to file our New Drug Application for accelerated approval in the\nfirst half of 2027. Given iopofosine I 131 has Breakthrough Therapy\nDesignation, we expect a six-month review with a potential approval by the end\nof 2027.”\n\nDetails of the upcoming poster presentation are as follows:\n\n Title:      “Iopofosine I 131 After BTK Inhibitors in Waldenström Macroglobulinemia: CLOVER-WaM Subgroup Efficacy and Safety”       \n Session #:  14                                                                                                                      \n Date/Time:  October 15, 2026, 4:00 PM                                                                                               \n Location:   Sierra-Ventura Hall                                                                                                     \n Presenter:  Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences                                                        \n\n\n\nAbout Cellectar Biosciences, Inc.\nCellectar Biosciences is a late-stage clinical biopharmaceutical company\nfocused on the discovery and development of proprietary drugs for the\ntreatment of cancer, independently and through research and development\ncollaborations. The company’s core objective is to leverage its proprietary\nPhospholipid Drug Conjugate™ (PDC) delivery platform to develop the\nnext-generation of cancer cell-targeting treatments, delivering improved\nefficacy and better safety as a result of fewer off-target effects.\n\nThe company’s product pipeline includes iopofosine I 131, which is a PDC\ndesigned to provide targeted delivery of iodine-131 (radioisotope). Iopofosine\nI 131 has been tested in Phase 2b trials as a treatment for relapsed or\nrefractory Waldenström Macroglobulinemia (WM), in relapsed or refractory\nmultiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2\nPhase 1b study is evaluating iopofosine I 131 in pediatric patients with\nhigh-grade gliomas, for which Cellectar is eligible to receive a Pediatric\nReview Voucher from the FDA upon approval. The FDA has granted iopofosine I\n131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track\nDesignations for various cancer indications, and the EMA has granted\niopofosine I 131 PRIority MEdicines (PRIME) designation.\n\nCellectar is also developing CLR 121125 (CLR 125), an iodine-125\nAuger-emitting program targeted for solid tumors, such as triple negative\nbreast (TNBC), lung, and colorectal cancer, and is currently being evaluated\nin a Phase 1b study for TNBC, which will determine the recommended dose for\nthe subsequent Phase 2 trial. CLR 125 has been well tolerated in vivo and\nhas demonstrated strong preclinical data showing reduction or inhibition of\nsolid tumor growth.\n\nIn addition to these assets, the Cellectar team is developing CLR 121225 (CLR\n225), an actinium-225 based program targeting solid tumors in indications with\nsignificant unmet need, such as pancreatic cancer, as well as proprietary\npreclinical PDC chemotherapeutic programs and multiple partnered PDC assets.\n\nFor more information, please visit https://www.cellectar.com/ or join the\nconversation by liking and following us on the company’s social media\nchannels: X\n(https://www.globenewswire.com/Tracker?data=G2AGN7TNZAM-SRMqRkvA9dIbzM9na-Io4rATl4ZqKqpTn1n5-9IOoJr9X2MnJn-6K5YD3mt-Vk-uGnahN-Gn9IDCoYmpbUqbvA-MkxRV27_h7EutxuTLGiQVm-nHEblGQc8pe-zgi9MzlRI969y0-HJgeMvAXIx7x5MzwCsn-cp0NPc5HUMfr0F6L3rlljTGkM0JSZjpPcwQjvsUiE39Kg==), LinkedIn\n(https://www.globenewswire.com/Tracker?data=j3lJ7d5MAYL1OPCKJnqYLPY7Dyw8oljaET_mlskSNz8KSJeLL4zrd0UIJWawfjnuidUNyZDXo7JsRs-pG8OIkP0fZBy4PLGsmRdaro5Q1tOHffai9LpxZnhDYxG2dMLcspGXTQrlYWac2ER4it1eKIK7zSkgLgFHJZnDxYnCczEQywDzebSiYdby2cr7dn6TxwiQWI2S9R0j9qSbL_XXbosEXego6GP5s_zgU2GIQ_rdm2sQ3GHh8HNsz9PvZOWISrhqsHpFQChkWCYL_LD_9w==),\nand Facebook\n(https://www.globenewswire.com/Tracker?data=EqH7Ubc2FBPUAadwELX_N2K5XM7bBevVYNJu2fG-2hy3nnnWwPbSbbnVnbLQRZXxFw0fVt2fnx_YCLIZKeHFReoVCCsvzvMdheSrz0QTrgBOpP6pYsCeKcp_rQacPQT-RDymZ7ac7GfZX-U1citjl-G8QEbg2qiaT7RVwN0X-dco1p1Jq1a74KEt_e8kP-XKDWzndCWmo0ye_8v4NJdx4ETngZ4OVN3YZUG_zOE26UFaoj2k0ZHDToKOCVBZMcLSfq7VNEvBNMWorM2ZlxgV7A==).\n\nForward Looking Statements Disclaimer \nThis news release contains forward-looking statements. You can identify these\nstatements by our use of words such as \"may,\" \"expect,\" \"believe,\"\n\"anticipate,\" \"intend,\" \"could,\" \"estimate,\" \"continue,\" \"plans,\" or their\nnegatives or cognates. These statements are only estimates and predictions and\nare subject to known and unknown risks and uncertainties that may cause actual\nfuture experience and results to differ materially from the statements made.\nThese statements are based on our current beliefs and expectations as to such\nfuture outcomes. Drug discovery and development involve a high degree of risk.\nFactors that might cause such a material difference include, among others,\nuncertainties related to the FDA and EMA regulatory pathways, ability to\nexecute strategic alternatives, identify suitable collaborators, partners,\nlicensees or purchasers for our product candidates and, if we are able to do\nso, to enter into binding agreements with regard to any of the foregoing, or\nto raise additional capital to support our operations, or our ability to fund\nour operations if we are unsuccessful with any of the foregoing. A complete\ndescription of risks and uncertainties related to our business is contained in\nour periodic reports filed with the Securities and Exchange Commission\nincluding our Form 10-K for the year ended December 31, 2025, and our Form\n10-Q for the quarterly period ending June 30, 2026. These forward-looking\nstatements are made only as of the date hereof, and we disclaim any obligation\nto update any such forward-looking statements.\n\nINVESTORS:\nAnne Marie Fields\nPrecision AQ\n212-362-1200\nannemarie.fields@precisionaq.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/980abc5d-826f-4ac3-ad81-f07d69b34af6)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6MjWrG-20260929","title":"Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia","author":"Globe Newswire","ticker":"CLRB","created":"2026-09-29T11:30:00.543Z","tickers":["CLRB"],"exchange":"NASDAQ","article_body":"Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and\nDuration of Response Exceeding 16 Months in Subset Analysis of Patients\nTreated with Iopofosine I 131 Immediately Post-BTKi Therapy\n\nData Further Support Company’s Plans to Advance Iopofosine I 131 in Phase 3\nConfirmatory Trial and Submit for U.S. Accelerated Market Approval in 1H27\n\nFLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences,\nInc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused\non the discovery and development of drugs for the treatment of cancer, today\nannounced that a subset analysis of data from the company’s Phase 2 CLOVER\nWaM clinical trial that support the potential of iopofosine I 131 as a\npotential treatment option for Waldenström Macroglobulinemia (WM) patients\nwho are refractory or resistant to BTK inhibitor therapy will be highlighted\nin a presentation at the upcoming International Workshop for Waldenström\nMacroglobulinemia (IWWM) taking place October 14 - 16, 2026 in Palm Springs,\nCalifornia.\n\n“We are pleased to present these data from the CLOVER-WaM study at IWWM and\nshare additional evidence supporting the potential of iopofosine I 131 to\naddress a significant unmet need for patients with WM. This analysis evaluated\npatients who received iopofosine I 131 immediately following BTK inhibitor\ntherapy after at least two prior lines of treatment, representing a\nparticularly challenging, heavily pretreated population,” said Jarrod\nLongcor, chief operating officer at Cellectar Biosciences. “We remain\non-target to dose patients in the confirmatory Phase 3 clinical trial in early\n2027 and to file our New Drug Application for accelerated approval in the\nfirst half of 2027. Given iopofosine I 131 has Breakthrough Therapy\nDesignation, we expect a six-month review with a potential approval by the end\nof 2027.”\n\nDetails of the upcoming poster presentation are as follows:\n\n Title:      “Iopofosine I 131 After BTK Inhibitors in Waldenström Macroglobulinemia: CLOVER-WaM Subgroup Efficacy and Safety”       \n Session #:  14                                                                                                                      \n Date/Time:  October 15, 2026, 4:00 PM                                                                                               \n Location:   Sierra-Ventura Hall                                                                                                     \n Presenter:  Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences                                                        \n\n\n\nAbout Cellectar Biosciences, Inc.\nCellectar Biosciences is a late-stage clinical biopharmaceutical company\nfocused on the discovery and development of proprietary drugs for the\ntreatment of cancer, independently and through research and development\ncollaborations. The company’s core objective is to leverage its proprietary\nPhospholipid Drug Conjugate™ (PDC) delivery platform to develop the\nnext-generation of cancer cell-targeting treatments, delivering improved\nefficacy and better safety as a result of fewer off-target effects.\n\nThe company’s product pipeline includes iopofosine I 131, which is a PDC\ndesigned to provide targeted delivery of iodine-131 (radioisotope). Iopofosine\nI 131 has been tested in Phase 2b trials as a treatment for relapsed or\nrefractory Waldenström Macroglobulinemia (WM), in relapsed or refractory\nmultiple myeloma (MM) and central nervous system (CNS) lymphoma. The CLOVER-2\nPhase 1b study is evaluating iopofosine I 131 in pediatric patients with\nhigh-grade gliomas, for which Cellectar is eligible to receive a Pediatric\nReview Voucher from the FDA upon approval. The FDA has granted iopofosine I\n131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track\nDesignations for various cancer indications, and the EMA has granted\niopofosine I 131 PRIority MEdicines (PRIME) designation.\n\nCellectar is also developing CLR 121125 (CLR 125), an iodine-125\nAuger-emitting program targeted for solid tumors, such as triple negative\nbreast (TNBC), lung, and colorectal cancer, and is currently being evaluated\nin a Phase 1b study for TNBC, which will determine the recommended dose for\nthe subsequent Phase 2 trial. CLR 125 has been well tolerated in vivo and\nhas demonstrated strong preclinical data showing reduction or inhibition of\nsolid tumor growth.\n\nIn addition to these assets, the Cellectar team is developing CLR 121225 (CLR\n225), an actinium-225 based program targeting solid tumors in indications with\nsignificant unmet need, such as pancreatic cancer, as well as proprietary\npreclinical PDC chemotherapeutic programs and multiple partnered PDC assets.\n\nFor more information, please visit https://www.cellectar.com/ or join the\nconversation by liking and following us on the company’s social media\nchannels: X\n(https://www.globenewswire.com/Tracker?data=G2AGN7TNZAM-SRMqRkvA9dIbzM9na-Io4rATl4ZqKqpTn1n5-9IOoJr9X2MnJn-6K5YD3mt-Vk-uGnahN-Gn9IDCoYmpbUqbvA-MkxRV27_h7EutxuTLGiQVm-nHEblGQc8pe-zgi9MzlRI969y0-HJgeMvAXIx7x5MzwCsn-cp0NPc5HUMfr0F6L3rlljTGkM0JSZjpPcwQjvsUiE39Kg==), LinkedIn\n(https://www.globenewswire.com/Tracker?data=j3lJ7d5MAYL1OPCKJnqYLPY7Dyw8oljaET_mlskSNz8KSJeLL4zrd0UIJWawfjnuidUNyZDXo7JsRs-pG8OIkP0fZBy4PLGsmRdaro5Q1tOHffai9LpxZnhDYxG2dMLcspGXTQrlYWac2ER4it1eKIK7zSkgLgFHJZnDxYnCczEQywDzebSiYdby2cr7dn6TxwiQWI2S9R0j9qSbL_XXbosEXego6GP5s_zgU2GIQ_rdm2sQ3GHh8HNsz9PvZOWISrhqsHpFQChkWCYL_LD_9w==),\nand Facebook\n(https://www.globenewswire.com/Tracker?data=EqH7Ubc2FBPUAadwELX_N2K5XM7bBevVYNJu2fG-2hy3nnnWwPbSbbnVnbLQRZXxFw0fVt2fnx_YCLIZKeHFReoVCCsvzvMdheSrz0QTrgBOpP6pYsCeKcp_rQacPQT-RDymZ7ac7GfZX-U1citjl-G8QEbg2qiaT7RVwN0X-dco1p1Jq1a74KEt_e8kP-XKDWzndCWmo0ye_8v4NJdx4ETngZ4OVN3YZUG_zOE26UFaoj2k0ZHDToKOCVBZMcLSfq7VNEvBNMWorM2ZlxgV7A==).\n\nForward Looking Statements Disclaimer \nThis news release contains forward-looking statements. You can identify these\nstatements by our use of words such as \"may,\" \"expect,\" \"believe,\"\n\"anticipate,\" \"intend,\" \"could,\" \"estimate,\" \"continue,\" \"plans,\" or their\nnegatives or cognates. These statements are only estimates and predictions and\nare subject to known and unknown risks and uncertainties that may cause actual\nfuture experience and results to differ materially from the statements made.\nThese statements are based on our current beliefs and expectations as to such\nfuture outcomes. Drug discovery and development involve a high degree of risk.\nFactors that might cause such a material difference include, among others,\nuncertainties related to the FDA and EMA regulatory pathways, ability to\nexecute strategic alternatives, identify suitable collaborators, partners,\nlicensees or purchasers for our product candidates and, if we are able to do\nso, to enter into binding agreements with regard to any of the foregoing, or\nto raise additional capital to support our operations, or our ability to fund\nour operations if we are unsuccessful with any of the foregoing. A complete\ndescription of risks and uncertainties related to our business is contained in\nour periodic reports filed with the Securities and Exchange Commission\nincluding our Form 10-K for the year ended December 31, 2025, and our Form\n10-Q for the quarterly period ending June 30, 2026. These forward-looking\nstatements are made only as of the date hereof, and we disclaim any obligation\nto update any such forward-looking statements.\n\nINVESTORS:\nAnne Marie Fields\nPrecision AQ\n212-362-1200\nannemarie.fields@precisionaq.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/980abc5d-826f-4ac3-ad81-f07d69b34af6)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-29T11:30:02.160394008Z","server_sent_at_ms":1790681402160},"received_at":"2026-09-29T11:30:02.246Z","source_url":null},"analysis":{"id":"143871","press_release_id":"155138","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["clinical-stage company dependent on raising additional capital to fund operations, per forward-looking statement risk factors","subset analysis of a Phase 2 trial — confirmatory Phase 3 data still pending"],"eventType":"clinical_trial","narrative":"Cellectar Biosciences will present Phase 2 CLOVER-WaM subset data at the International Workshop for Waldenström Macroglobulinemia (Oct 14-16, Palm Springs) showing iopofosine I 131 achieved a 79.2% major response rate and 87.5% overall response rate in WM patients refractory/resistant to BTK inhibitor therapy.\n\nDuration of response exceeded 16 months in patients treated immediately post-BTKi after at least two prior lines of treatment — a heavily pretreated population with significant unmet need.\n\nManagement reaffirmed plans to dose the confirmatory Phase 3 trial in early 2027 and file for U.S. accelerated approval in 1H27, with a potential approval by end of 2027 given Breakthrough Therapy Designation.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Strong post-BTKi subset data (79.2% MRR) de-risks the 1H27 accelerated-approval filing path for iopofosine I 131."},"keyFigures":{"drugName":"iopofosine I 131","phaseOfTrial":"Phase 2","customDimensions":{"phase3_dosing":"early 2027","approval_filing":"NDA for accelerated approval in 1H27","potential_approval":"end of 2027 (six-month review under Breakthrough Therapy Designation)","major_response_rate":"79.2%","duration_of_response":">16 months","overall_response_rate":"87.5%"}},"quotedText":"We remain on-target to dose patients in the confirmatory Phase 3 clinical trial in early 2027 and to file our New Drug Application for accelerated approval in the first half of 2027.","namedEntities":{"people":[{"name":"Jarrod Longcor","role":"Chief Operating Officer"},{"name":"Anne Marie Fields","role":"investor relations contact, Precision AQ"}],"products":["iopofosine I 131","CLR 121125 (CLR 125)","CLR 121225 (CLR 225)","Phospholipid Drug Conjugate (PDC) platform"],"companies":[{"name":"Cellectar Biosciences, Inc.","ticker":"CLRB","relationship":"filer"},{"name":"Precision AQ","relationship":"investor relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Positive Phase 2 CLOVER-WaM subset data (MRR 79.2%, ORR 87.5%) presented at a conference supports the Phase 3/accelerated-approval path, but it is a data presentation, not a binary regulatory or pivotal readout."},"tickerRelevance":{"others":[],"primary":"CLRB"},"globalImportance":30,"audienceRelevance":22,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap clinical biotech","eventGravity":"conference data presentation, not binary catalyst","issuerAuthored":true,"retailFavoriteBoost":"small biotech with catalyst path"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Cellectar Biosciences will present Phase 2 CLOVER-WaM subset data at the International Workshop for Waldenström Macroglobulinemia (Oct 14-16, Palm Springs) showing iopofosine I 131 achieved a 79.2% major response rate and 87.5% overall response rate in WM patients refractory/resistant to BTK inhibitor therapy.\n\nDuration of response exceeded 16 months in patients treated immediately post-BTKi after at least two prior lines of treatment — a heavily pretreated population with significant unmet need.\n\nManagement reaffirmed plans to dose the confirmatory Phase 3 trial in early 2027 and file for U.S. accelerated approval in 1H27, with a potential approval by end of 2027 given Breakthrough Therapy Designation.","key_figures":{"drugName":"iopofosine I 131","phaseOfTrial":"Phase 2","customDimensions":{"phase3_dosing":"early 2027","approval_filing":"NDA for accelerated approval in 1H27","potential_approval":"end of 2027 (six-month review under Breakthrough Therapy Designation)","major_response_rate":"79.2%","duration_of_response":">16 months","overall_response_rate":"87.5%"}},"named_entities":{"people":[{"name":"Jarrod Longcor","role":"Chief Operating Officer"},{"name":"Anne Marie Fields","role":"investor relations contact, Precision AQ"}],"products":["iopofosine I 131","CLR 121125 (CLR 125)","CLR 121225 (CLR 225)","Phospholipid Drug Conjugate (PDC) platform"],"companies":[{"name":"Cellectar Biosciences, Inc.","ticker":"CLRB","relationship":"filer"},{"name":"Precision AQ","relationship":"investor relations firm"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T11:30:08.971Z","global_importance":30,"audience_relevance":22,"importance_components":{"tickerTier":"micro-cap clinical biotech","eventGravity":"conference data presentation, not binary catalyst","issuerAuthored":true,"retailFavoriteBoost":"small biotech with catalyst path"}},"durationMs":6649,"modelName":"glm-5.3-flashx"}}